Literature DB >> 525996

Amantadine aerosol in humans.

V Knight, K Bloom, S Z Wilson, R K Wilson.   

Abstract

Seven well volunteers and three patients with a naturally occurring influenza A/USSR/77 (H1N1)-like infection were given amantadine by small-particle aerosol with a Collison generator modified for this purpose. Inhalation periods for the volunteers were increased on consecutive weekends from 15 min to 1 h, 4 h, 9 h, and 2 consecutive days of 6 h each. The particle size was 1.2-micrometer mass median diameter, and the concentration of inhaled aerosol ranged from 47 to 75 microgram/liter. Estimates of retained doses in 9 h were 74 to 149 mg. About two-thirds of the dose was recovered in the urine. Pulmonary function studies did not vary significantly from base-line values and were within a normal range for five of seven volunteers. Two volunteers with a moderate reduction in mid-maximal flow before exposure had a total of three episodes of coughing and wheezing associated with moderate reductions in mid-maximal flow values. These episodes cleared spontaneously or improved promptly after isoproterenol therapy. The patients with influenza tolerated the treatment well and recovered promptly.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 525996      PMCID: PMC352907          DOI: 10.1128/AAC.16.5.572

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Clinical usefulness of the single-breath pulmonucy diffusing capacity test.

Authors:  B BURROWS; J E KASIK; A H NIDEN; W R BARCLAY
Journal:  Am Rev Respir Dis       Date:  1961-12

2.  Small-particle aerosols of antiviral compounds in treatment of type A influenza pneumonia in mice.

Authors:  J S Walker; E L Stephen; R O Spertzel
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

3.  Amantadine small-particle aerosol: generation and delivery to man.

Authors:  S Z Wilson; V Knight; R Moore; E W Larson
Journal:  Proc Soc Exp Biol Med       Date:  1979-07

4.  Spirometric standards for healthy nonsmoking adults.

Authors:  J F Morris; A Koski; L C Johnson
Journal:  Am Rev Respir Dis       Date:  1971-01

5.  Continuous aerosol therapy system using a modified Collison nebulizer.

Authors:  H W Young; J W Dominik; J S Walker; E W Larson
Journal:  J Clin Microbiol       Date:  1977-02       Impact factor: 5.948

6.  Airway hyperreactivity and peripheral airway dysfunction in influenza A infection.

Authors:  J W Little; W J Hall; R G Douglas; G S Mudholkar; D M Speers; K Patel
Journal:  Am Rev Respir Dis       Date:  1978-08
  6 in total
  4 in total

1.  Safety and pharmacokinetics of rimantadine small-particle aerosol.

Authors:  R L Atmar; S B Greenberg; J M Quarles; S Z Wilson; B Tyler; S Feldman; R B Couch
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of amantadine hydrochloride.

Authors:  F Y Aoki; D S Sitar
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

3.  Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice.

Authors:  S Z Wilson; V Knight; P R Wyde; S Drake; R B Couch
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

Review 4.  Antiviral chemotherapy and prophylaxis of viral respiratory disease.

Authors:  S J Sperber; F G Hayden
Journal:  Clin Lab Med       Date:  1987-12       Impact factor: 1.935

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.